A detailed history of Two Sigma Investments, LP transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Two Sigma Investments, LP holds 56,933 shares of PRLD stock, worth $58,640. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56,933
Previous 43,135 31.99%
Holding current value
$58,640
Previous $164,000 28.66%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.07 - $6.37 $28,561 - $87,893
13,798 Added 31.99%
56,933 $117,000
Q2 2024

Aug 14, 2024

SELL
$3.32 - $5.63 $57,973 - $98,311
-17,462 Reduced 28.82%
43,135 $164,000
Q1 2024

May 15, 2024

BUY
$2.68 - $4.84 $6,198 - $11,194
2,313 Added 3.97%
60,597 $287,000
Q4 2023

Feb 14, 2024

BUY
$1.69 - $4.37 $76,845 - $198,708
45,471 Added 354.88%
58,284 $248,000
Q3 2023

Nov 14, 2023

SELL
$2.74 - $4.79 $72,546 - $126,824
-26,477 Reduced 67.39%
12,813 $39,000
Q2 2023

Aug 14, 2023

BUY
$4.45 - $8.12 $74,915 - $136,700
16,835 Added 74.97%
39,290 $176,000
Q1 2023

May 15, 2023

SELL
$4.58 - $7.34 $134,848 - $216,111
-29,443 Reduced 56.73%
22,455 $127,000
Q4 2022

Feb 14, 2023

SELL
$4.61 - $8.5 $247,570 - $456,475
-53,703 Reduced 50.85%
51,898 $313,000
Q3 2022

Nov 14, 2022

SELL
$5.0 - $8.82 $591,175 - $1.04 Million
-118,235 Reduced 52.82%
105,601 $698,000
Q2 2022

Aug 15, 2022

BUY
$4.0 - $7.55 $173,696 - $327,851
43,424 Added 24.07%
223,836 $1.17 Million
Q1 2022

May 16, 2022

SELL
$6.9 - $13.22 $706,297 - $1.35 Million
-102,362 Reduced 36.2%
180,412 $1.25 Million
Q4 2021

Feb 14, 2022

BUY
$11.89 - $31.74 $3.36 Million - $8.98 Million
282,774 New
282,774 $3.52 Million
Q3 2021

Nov 15, 2021

SELL
$25.78 - $38.65 $260,790 - $390,983
-10,116 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$28.63 - $44.3 $289,621 - $448,138
10,116 New
10,116 $290,000

Others Institutions Holding PRLD

About Prelude Therapeutics Inc


  • Ticker PRLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,369,200
  • Market Cap $37.5M
  • Description
  • Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...
More about PRLD
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.